
Vertex Pharmaceuticals: A Painful Setback? Or Golden Opportunity?
Vertex Pharmaceuticals Stumbles on Trial Results Vertex Pharmaceuticals experienced a significant drop in its stock, falling 13%, after revealing underwhelming results from a late-stage clinical trial. Known for its dominating treatments in the cystic fibrosis (CF) market, Vertex has been aiming to